Akebia Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
AKBA$0.54+1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Three Months Ended March 31, | ||
|---|---|---|
| (dollars in thousands) | 2026 | 2025 |
| Operating Activities: | ||
| Net income (loss) | $(9,054) | $6,112 |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Depreciation | 328 | 314 |
| Bad debt expense | 199 | 702 |
| Change in fair value of warrant liability | (456) | (155) |
| Non-cash royalty revenue related to sale of future royalties | (341) | (369) |
| Non-cash interest expense | 4,577 | 6,253 |
| Non-cash operating lease expense | 1,198 | 1,104 |
| Write-down of inventory | 3,216 | 163 |
| Gain on the sale of property and equipment | — | (172) |
| Stock-based compensation expense | 3,668 | 2,187 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (15,704) | (27,872) |
| Inventory | (2,540) | (4,953) |
| Prepaid expenses and other current assets | 170 | 2,212 |
| Other long-term assets | (749) | 54 |
| Accounts payable | (7,792) | (2,234) |
| Accrued expense and other current liabilities | 2,035 | 2,771 |
| Operating lease liabilities | (1,422) | (1,310) |
| Deferred revenue | 1,815 | 1,241 |
| Other long-term liabilities | (355) | 365 |
| Net cash used in operating activities | (21,207) | (13,587) |
| Investing Activities: | ||
| Purchases of equipment | (62) | (18) |
| Proceeds from the sale of property and equipment | — | 172 |
| Net cash provided by (used in) investing activities | (62) | 154 |
| Financing Activities: | ||
| Proceeds from the issuance of debt | — | 10,000 |
| Payments of issuance costs related to BlackRock Credit Agreement | — | (63) |
| Proceeds from issuance of common stock, net of issuance costs | — | 64,907 |
| Proceeds from issuance of stock under employee stock purchase plan | 131 | 78 |
| Proceeds from the exercise of stock options | 20 | 482 |
| Repayment of WCF liability | (492) | — |
| Repayment of liability related to settlement royalties | (585) | — |
| Repayment of term debt | — | (462) |
| Net cash provided by (used in) financing activities | (926) | 74,942 |
| Increase (decrease) in cash, cash equivalents and restricted cash | (22,195) | 61,509 |
| Cash, cash equivalents and restricted cash — beginning of period | 186,543 | 53,550 |
| Cash, cash equivalents and restricted cash — end of period | $164,348 | $115,059 |
| Non-cash financing activities | ||
| Issuance of warrants in connection with BlackRock Credit Agreement | $— | $2,199 |
| Purchase of IPR&D asset included in accrued expenses and other current liabilities | $5,000 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.